腺苷脱氨酶1在肺腺癌组织中的表达及临床意义

杨文娣; 余钱; 郭政军; 张晓月; 彭媛; 杨镇洲

doi:10.16016/j.1000-5404.202106070

您当前的位置：

首页 >

文章列表页 >

腺苷脱氨酶1在肺腺癌组织中的表达及临床意义

临床医学 | 更新时间：2026-01-09

- 腺苷脱氨酶1在肺腺癌组织中的表达及临床意义
- Expression and clinical significance of adenosine deaminase acting on RNA-1 in lung adenocarcinoma
- 第三军医大学学报 2021年43卷第24期页码：2683-2687
- 作者机构：
  
  400010 重庆，重庆医科大学附属第二医院肿瘤中心
- 作者简介：
  
  [ 杨镇洲，E-mail: yangzz@cqmu.edu.cn YANG Zhenzhou, E-mail: yangzz@cqmu.edu.cn
- 基金信息：
  
  重庆医科大学附属第二医院“宽仁英才”项目(202007);重庆市自然科学基金博士后科学基金(cstc2019jcyj-bshX0056)
- DOI：10.16016/j.1000-5404.202106070
  中图分类号： R345;R730.43;R734.2
- 收稿：2021-06-08，
  
  修回：2021-07-03，
  
  纸质出版：2021-12-30
- 稿件说明：
移动端阅览
杨文娣, 余钱, 郭政军, 等. 腺苷脱氨酶1在肺腺癌组织中的表达及临床意义[J]. 第三军医大学学报, 2021,43(24):2683-2687.

Wendi YANG, Qian YU, Zhengjun GUO, et al. Expression and clinical significance of adenosine deaminase acting on RNA-1 in lung adenocarcinoma[J]. Journal of Third Military Medical University, 2021, 43(24): 2683-2687.
杨文娣, 余钱, 郭政军, 等. 腺苷脱氨酶1在肺腺癌组织中的表达及临床意义[J]. 第三军医大学学报, 2021,43(24):2683-2687. DOI： 10.16016/j.1000-5404.202106070.

Wendi YANG, Qian YU, Zhengjun GUO, et al. Expression and clinical significance of adenosine deaminase acting on RNA-1 in lung adenocarcinoma[J]. Journal of Third Military Medical University, 2021, 43(24): 2683-2687. DOI： 10.16016/j.1000-5404.202106070.

摘要

目的

探讨RNA特异性腺苷脱氨酶1(adenosine deaminase acting on RNA-1，ADAR1)在肺腺癌组织中的表达及其与患者临床病理特征和预后的相关性。

方法

通过免疫组织化学染色法检测2015年12月至2017年9月本院收治的131例肺腺癌患者术后组织标本以及相应癌旁组织中ADAR1的表达，分析ADAR1蛋白的表达与患者临床病理参数的关系，并利用Kaplan-Meier法分析ADAR1表达水平和患者总生存期(overall survival，OS)的关系，拟合Cox模型评价不同指标的预后价值。

结果

肺腺癌组织中ADAR1蛋白表达量为77.9%

显著高于相应配对的癌旁组织(12.5%，

0.01)，且ADAR1表达与患者临床分期和淋巴结转移有关(

0.05)，Kaplan-Meier分析表明ADAR1高表达与较短的OS显著相关(

=2.671，95%

：1.282~5.563

0.01)；多因素Cox回归分析显示，临床分期和淋巴结转移(

0.01)可作为肺腺癌患者预后评估的独立危险因素。

结论

ADAR1在肺腺癌组织中高表达，且肺腺癌患者中ADAR1高表达提示预后不良。

Abstract

Objective

To investigate the expression of adenosine deaminase acting on RNA-1 (ADAR1) in lung adenocarcinoma and its association with clinicopathological characteristics and prognosis.

Methods

Immunohistochemical staining was applied to detect the expression of ADAR1 in the tumor tissues and corresponding adjacent normal tissues of 131 patients with lung adenocarcinoma treated in our hospital from December 2015 to September 2017. The association between the expression of ADAR1 protein and clinicopathological parameters was analyzed. Kaplan-Meier analysis was performed to analyze the correlation between ADAR1 level and patients' overall survival (OS)

and fitting Cox model was used to evaluate the prognostic values of different indixes.

Results

ADAR1 was highly expressed in 102 cases (77.9%) of the patients

while only 21 cases (12.5%) of paired para-carcinoma tissues

indicating a significant difference (

0.001)

and the level of ADAR1 was correlated with clinical stage and lymph node metastasis (

0.05). Kaplan-Meier analysis showed that higher expression of ADAR1 was remarkably associated with shorter OS (

=2.671

95%

: 1.282~5.563

0.01). Multivariate Cox regression analysis suggested that clinical stage and lymph node metastasis (

0.01) were independent risk factors for prognosis of the patients.

Conclusion

ADAR1 is highly expressed in lung adenocarcinoma tissues

and the patients with higher expression indicate poorer prognosis.

关键词

Keywords

references

SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

CHEN Z, FILLMORE C M, HAMMERMAN P S, et al . Non-small-cell lung cancers: a heterogenyeous set of diseases[J ] . Nat Rev Cancer, 2014, 14(8): 535-546. DOI: 10.1038/nrc3775.

MILLER K D, NOGUEIRA L, MARIOTTO A B, et al . Cancer treatment and survivorship statistics, 2019[J ] . CA Cancer J Clin, 2019, 69(5): 363-385. DOI: 10.3322/caac.21565.

GALEANO F, TOMASELLI S, LOCATELLI F, et al . A-to-I RNA editing: The "ADAR" side of human cancer[J ] . Semin Cell Dev Biol, 2012, 23(3): 244-250. DOI: 10.1016/j.semcdb.2011.09.003.

ZHANG Y, QIAN H Z, XU J, et al . ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications[J ] . Ann Transl Med, 2019, 7(22): 686. DOI: 10.21037/atm.2019.11.06.

HU X, CHEN J, SHI X, et al . RNA editing of AZIN 1 induces the malignant progression of non-small-cell lung can-cers[J ] . Tumour Biol, 2017, 39(8): 1010428317700001. DOI: 10.1177/1010428317700001..

SHOSHAN E, MOBLEY A K, BRAEUER R R, et al . Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis[J ] . Nat Cell Biol, 2015, 17(3): 311-321. DOI: 10.1038/ncb3110.

QIN Y R, QIAO J J, CHAN T H, et al . Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma[J ] . Cancer Res, 2014, 74(3): 840-851. DOI: 10.1158/0008-5472.CAN-13-2545.

NAKANO M, FUKAMI T, GOTOH S, et al . A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer[J ] . J Biol Chem, 2017, 292(12): 4873-4884. DOI: 10.1074/jbc.m117.775684.

CHEN W, HE W, CAI H, et al . A-to-I RNA editing of BLCAP lost the inhibition to STAT3 activation in cervical cancer[J ] . Oncotarget, 2017, 8(24): 39417-39429. DOI: 10.18632/oncotarget.17034.

TEOH P J, AN O, CHUNG T H, et al . Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis[J ] . Blood, 2018, 132(12): 1304-1317. DOI: 10.1182/blood-2018-02-832576.

FRITZELL K, XU L D, LAGERGREN J, et al . ADARs and editing: The role of A-to-I RNA modification in cancer progression[J ] . Semin Cell Dev Biol, 2018, 79: 123-130. DOI: 10.1016/j.semcdb.2017.11.018.

EISENBERG E. Proteome diversification by RNA editing[J]. Methods Mol Biol, 2021, 2181: 229-251. DOI: 10.1007/978-1-0716-0787-9_14.

LIDDICOAT B J, PISKOL R, CHALK A M, et al . RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself[J ] . Science, 2015, 349(6252): 1115-1120. DOI: 10.1126/science.aac7049.

NEMLICH Y, BARUCH E N, BESSER M J, et al . ADAR1-mediated regulation of melanoma invasion[J ] . Nat Commun, 2018, 9(1): 2154. DOI: 10.1038/s41467-018-04600-2.

SAMUEL C E. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses[J]. J Biol Chem, 2019, 294(5): 1710-1720. DOI: 10.1074/jbc.tm118.004166.

PAZ N, LEVANON E Y, AMARIGLIO N, et al . Altered adenosine-to-inosine RNA editing in human cancer[J ] . Genome Res, 2007, 17(11): 1586-1595. DOI: 10.1101/gr.6493107.

AMIN E M, LIU Y, DENG S, et al . The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizingFAK[J ] . Sci Signal, 2017, 10(497): eaah3941. DOI: 10.1126/scisignal.aah3941.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肺腺癌相关tsRNA的筛选和验证

长链非编码RNA SFTA1P在肺腺癌中的表达及预后预测研究

PSMA4在肺腺癌预后、诊断和免疫浸润中的作用和机制研究

基于中国人群的雌激素受体表达新分层（低/中/高）可更精准地预测HR⁺/HER2^-早期乳腺癌患者的预后

转录因子TGIF1高表达胃癌的免疫抑制性微环境特征及临床意义分析